Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 16/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 16/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.54 |
| ▸ | ATP4A | P20648 | 1/20 | 0.43 |
| ▸ | ATP4B | P51164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1816224 | 0.91 | CYP3A4 (0.48) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1814981 | 0.91 | CYP3A4 (0.50) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| Pumaprazole SCHEMBL29493303 | 0.89 | CYP3A4 (0.69) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| Pumaprazole SCHEMBL451376 | 0.89 | CYP3A4 (0.69) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL9099268 | 0.88 | CYP3A4 (0.55) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL10396997 | 0.88 | CYP3A4 (0.51) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL7492158 | 0.88 | CYP3A4 (0.61) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL9097344 | 0.87 | CYP3A4 (0.54) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| Hydrochloric Acid SCHEMBL10397533 | 0.87 | CYP3A4 (0.50) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL8136776 | 0.85 | CYP3A4 (0.53) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0841904-B1 | ORAL PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE OF REVERSIBLE PROTON PUMP INHIBITORS | ALTANA PHARMA AG (DE) | 2003-02-05 | — | — | EP | claimed |
| US-6132768-A | FOR TREATING DISORDERS CAUSED BY HELICOBACTER | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-10-17 | — | — | US | claimed |
| EP-0683780-B1 | IMIDAZOPYRIDINES AND THEIR USE IN TREATING GASTROINTESTINAL DISEASES | BYK GULDEN LOMBERG CHEM FAB (DE) | 2000-04-26 | — | — | EP | claimed |
| EP-0841904-A1 | ORAL PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE OF REVERSIBLE PROTON PUMP INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1998-05-20 | — | — | EP | claimed |
| WO-1997002021-A1 | ORAL PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE OF REVERSIBLE PROTON PUMP INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-01-23 | — | — | WO | claimed |
| EP-0683780-A1 | IMIDAZOPYRIDINES AND THEIR USE IN TREATING GASTROINTESTINAL DISEASES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1995-11-29 | — | — | EP | claimed |
| WO-1994018199-A1 | IMIDAZOPYRIDINES AND THEIR USE IN TREATING GASTROINTESTINAL DISEASES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1994-08-18 | — | — | WO | claimed |
| US-7951398-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | NYCOMED GMBH (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20090048287-A1 | Compositions useful for treating gastrointestinal motility disorders | EDUSA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20070122474-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG | 2007-05-31 | — | — | US | disclosed |
| US-7175854-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20060189648-A1 | Compositions useful for increasing lower esophageal sphincter pressure | EDUSA PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1663313-A2 | COMPOSITIONS USEFUL FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | Dynogen Pharmaceuticals Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20040058896-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | US | disclosed |
| EP-1341527-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA Pharma AG (DE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| EP-0683780-B1 | IMIDAZOPYRIDINES AND THEIR USE IN TREATING GASTROINTESTINAL DISEASES | BYK GULDEN LOMBERG CHEM FAB (DE) | 2000-04-26 | — | — | EP | disclosed |
| US-5665730-A | GASTROINTESTINAL DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-09-09 | — | — | US | disclosed |
| EP-0683780-A1 | IMIDAZOPYRIDINES AND THEIR USE IN TREATING GASTROINTESTINAL DISEASES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1995-11-29 | — | — | EP | disclosed |
| WO-1994018199-A1 | IMIDAZOPYRIDINES AND THEIR USE IN TREATING GASTROINTESTINAL DISEASES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1994-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048287-A1 | Compositions useful for treating gastrointestinal motility disorders | HRH2, MLNR, HTR3A | CYP3A4 1306/4885CYP2C9 1083/4885CYP2D6 620/4885 |
| US-20060189648-A1 | Compositions useful for increasing lower esophageal sphincter pressure | HTR3A, HTR3D, HTR3B | CYP3A4 2764/4885CYP2C9 2333/4885CYP2D6 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.